Editorial: Antifungal Drug Discovery: New Theories and New Therapies

Seneviratne, Chaminda Jayampath; Rosa, Edvaldo Antônio Ribeiro

doi:10.3389/fmicb.2016.00728

Cited by 20 publications

(16 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Resistance mechanisms were described for all commercially available antifungal agents ( Table 2 ). Rising antifungal resistance is a major problem especially in case of fluconazole, a drug of choice for candidiasis treatment in AIDS patients [ 22 ]. Recent surveillance studies from various medical centers worldwide have documented the rise in echinocandins’ resistance; especially among C. glabrata isolates [ 14 , 19 , 23 ].…”

Section: Introductionmentioning

confidence: 99%

Natural Antimicrobial Peptides as Inspiration for Design of a New Generation Antifungal Compounds

Bondaryk

Staniszewska

Zielińska

et al. 2017

JoF

100

View full text Add to dashboard Cite

Invasive fungal infections are associated with high mortality rates, despite appropriate antifungal therapy. Limited therapeutic options, resistance development and the high mortality of invasive fungal infections brought about more concern triggering the search for new compounds capable of interfering with fungal viability and virulence. In this context, peptides gained attention as promising candidates for the antimycotics development. Variety of structural and functional characteristics identified for various natural antifungal peptides makes them excellent starting points for design novel drug candidates. Current review provides a brief overview of natural and synthetic antifungal peptides.

show abstract

Section: Introductionmentioning

confidence: 99%

Natural Antimicrobial Peptides as Inspiration for Design of a New Generation Antifungal Compounds

Bondaryk

Staniszewska

Zielińska

et al. 2017

JoF

100

View full text Add to dashboard Cite

show abstract

“…This scenario becomes more complicated if we take into consideration the challenges related to the development of new antifungal agents. The fact that fungi are evolutionarily close to their human host impairs the discovery of new compounds with selective action ( Seneviratne and Rosa, 2016 ). These factors associated with increases in antifungal resistance ( Pfaller, 2012 ), emergence of uncommon fungi ( Davoudi et al, 2015 ; Roilides, 2016 ), and high mortality rates ( Brown et al, 2012 ; Gaffi – Global Action Fund for Fungal Infections, 2016 ) have led the scientific community to search for other ways to improve drug targeting and efficacy while reducing adverse effects.…”

Section: Introductionmentioning

confidence: 99%

Potential Use of Alginate-Based Carriers As Antifungal Delivery System

2017

View full text Add to dashboard Cite

Fungal infections have become a major public health problem, growing in number and severity in recent decades due to an increase of immunocompromised patients. The use of therapeutic agents available to treat these fungal infections is limited by their toxicity, low bioavailability, antifungal resistance, and high cost of treatment. Thus, it becomes extremely important to search for new therapeutic options. The use of polymeric systems as drug carriers has emerged as a promising alternative to conventional formulations for antifungals. Alginate is a natural polymer that has been explored in the last decade for development of drug delivery systems due to its non-toxicity, biodegradability, biocompatibility, low cost, mucoadhesive, and non-immunogenic properties. Several antifungal agents have been incorporated in alginate-based delivery systems, including micro and nanoparticles, with great success, displaying promising in vitro and in vivo results for antifungal activities, reduction in the toxicity and the total drug dose used in the treatment, and improved bioavailability. This review aims at discussing the potential use and benefits of alginate-based nanocarriers and other delivery systems containing antifungal agents in the therapy of fungal infections.

show abstract

“…Oral candidiasis is the most common opportunistic fungal infection of the oral cavity and represents a significant clinical problem, especially in elderly denture wearers, HIV-infected individuals, and patients undergoing antineoplastic therapy (Coronado-Castellote and Jimenez-Soriano, 2013;Garcia-Cuesta et al, 2014;Seneviratne and Rosa, 2016;Zhang et al, 2016;Venkatasalu et al, 2020). The manifestations of oral candidiasis can occur in the lips, skin, and mucosa and have different clinical and histopathological variants (Coronado-Castellote and Jimenez-Soriano, 2013;Costa et al, 2013b;Zhang et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

Streptococcus mutans Secreted Products Inhibit Candida albicans Induced Oral Candidiasis

et al. 2020

View full text Add to dashboard Cite

In the oral cavity, Candida species form mixed biofilms with Streptococcus mutans, a pathogenic bacterium that can secrete quorum sensing molecules with antifungal activity. In this study, we extracted and fractioned culture filtrate of S. mutans, seeking antifungal agents capable of inhibiting the biofilms, filamentation, and candidiasis by Candida albicans. Active S. mutans UA159 supernatant filtrate components were extracted via liquid-liquid partition and fractionated on a C-18 silica column to resolve S. mutans fraction 1 (SM-F1) and fraction 2 (SM-F2). We found anti-biofilm activity for both SM-F1 and SM-F2 in a dose dependent manner and fungal growth was reduced by 2.59 and 5.98 log for SM-F1 and SM-F2, respectively. The SM-F1 and SM-F2 fractions were also capable of reducing C. albicans filamentation, however statistically significant differences were only observed for the SM-F2 (p = 0.004). SM-F2 efficacy to inhibit C. albicans was confirmed by its capacity to downregulate filamentation genes CPH1, EFG1, HWP1, and UME6. Using Galleria mellonella as an invertebrate infection model, therapeutic treatment with SM-F2 prolonged larvae survival. Examination of the antifungal capacity was extended to a murine model of oral candidiasis that exhibited a reduction in C. albicans colonization (CFU/mL) in the oral cavity when treated with SM-F1 (2.46 log) and SM-F2 (2.34 log) compared to the control (3.25 log). Although both SM-F1 and SM-F2 fractions decreased candidiasis in mice, only SM-F2 exhibited significant quantitative differences compared to the non-treated group for macroscopic lesions, hyphae invasion, tissue lesions, and inflammatory infiltrate. Taken together, these results indicate that the SM-F2 fraction contains antifungal components, providing a promising resource in the discovery of new inhibitors for oral candidiasis.

show abstract

Editorial: Antifungal Drug Discovery: New Theories and New Therapies

Cited by 20 publications

References 20 publications

Natural Antimicrobial Peptides as Inspiration for Design of a New Generation Antifungal Compounds

Natural Antimicrobial Peptides as Inspiration for Design of a New Generation Antifungal Compounds

Potential Use of Alginate-Based Carriers As Antifungal Delivery System

Streptococcus mutans Secreted Products Inhibit Candida albicans Induced Oral Candidiasis

Contact Info

Product

Resources

About